5-Alkynyl Pyrimidines as Selective PI3Kα and mTOR Kinase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective inhibitors for the PI3K and mTOR pathways, which are crucial in cancer development and progression, due to limitations in targeting these pathways specifically and safely.
Innovation Solution
Development of 5-alkynyl-pyrimidines with specific structural groups that act as inhibitors of PI3Kα and mTOR, offering a therapeutic approach to treat cancers and other diseases characterized by abnormal cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing kinase inhibitors are used to target PI3K and mTOR pathways, then cancer treatment efficacy is improved, but off-target effects and toxicity increase due to lack of specificity
Solution Approach 1:
The patent applies local quality by introducing specific structural features (5-alkynyl pyrimidine core with particular substituent patterns) that create selective binding characteristics. The compound structure includes specific R1-R5 groups that confer PI3Kα and mTOR selectivity, allowing the inhibitor to target these specific pathways while minimizing off-target effects on other kinases.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations) to optimize the binding affinity and selectivity profile. By adjusting the chemical parameters of the pyrimidine core and its substituents, the compounds achieve high efficacy against PI3Kα and mTOR while maintaining safety margins.
2Adaptability or versatility
If broad-spectrum kinase inhibitors are developed to cover multiple pathways, then therapeutic versatility is improved, but safety profile deteriorates due to increased toxicity
Solution Approach 1:
The patent applies universality by designing a single molecular framework (5-alkynyl pyrimidine) that can inhibit multiple targets (PI3Kα and mTOR) through a unified mechanism. This multi-functional approach allows the compounds to address different cancer subtypes and pathways without requiring multiple separate drug molecules, thereby improving versatility while maintaining a manageable safety profile through consistent mechanism of action.
3Object-affected harmful factors
If novel kinase inhibitors are synthesized to improve specificity, then off-target effects are reduced, but development time and complexity increase
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional modules: the pyrimidine core provides the basic kinase inhibitory activity, while specific substituent groups (R1-R5) confer selectivity and pharmacological properties. This modular approach allows independent optimization of each component to achieve high specificity without requiring complete redesign of the entire molecule, thereby reducing development complexity.
Data Source
AI summary
The present invention encompasses compounds of general formula (1) wherein R1 to R4 R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.